|
|
 |
|
Viewing report
|
|
|
|
Balaglitazone (DRF 2593, NN2344) - R & D Biopharmaceutical & Pharmaceutical Product Profile
BioPolaris, March 2010, Pages: 1
Balaglitazone (DRF 2593, NN2344) - R & D Biopharmaceutical & Pharmaceutical Product Profile
Balaglitazone (DRF 2593, NN2344) is a late-stage R & D therapeutic product.
Sources of Information:
Research data published in this product profile are obtained primarily from companies involved in its development. In addition, the analyst used other available sources of information, including database of the US National Institutes of Health (NIH).
Rarely, and only when necessary, information was based on published scientific articles.
Customers who bought this item also bought
UNI-rE-4 (rExendin-4) - R & D Biopharmaceutical & Pharmaceutical Product Profile
Coagulation Factors 2010 - The Portfolio Aspect as Decisive Force: A Competitive Landscape and R&D Pipeline Analysis of Hemostasis Proteins
Cetilistat (ATL-962) - R & D Biopharmaceutical & Pharmaceutical Product Profile
Taspoglutide - R & D Biopharmaceutical & Pharmaceutical Product Profile
Albiglutide - R & D Biopharmaceutical & Pharmaceutical Product Profile
Alogliptin (SYR-322) - R & D Biopharmaceutical & Pharmaceutical Product Profile
HDV-Insulin (HDV-I) - R & D Biopharmaceutical & Pharmaceutical Product Profile
IN-105 - R & D Biopharmaceutical & Pharmaceutical Product Profile
Linagliptin (Ondero®, BI 1356) - R & D Biopharmaceutical & Pharmaceutical Product Profile
LY2189265 - R & D Biopharmaceutical & Pharmaceutical Product Profile
|
|
|
|
